



Solenio Therapeutics to Present at the 2019 H.C. Wainwright Global Life Sciences Conference

April 3, 2019 12:00 PM EDT

REDWOOD CITY, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Solenio") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present at the 2019 H.C. Wainwright Global Life Sciences Conference on Monday, April 8, 2019, at 4:50 PM BST / 11:50 AM ET, in London, United Kingdom. A webcast of the presentation will be available here: <http://wsw.com/webcast/hcw4/slno/>.

About Soleno Therapeutics, Inc.

Solenio is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, is currently being evaluated in a Phase III clinical development program.

For more information, please visit www.solenio.life.

CONTACT:

Brian Ritchie
LifeSci Advisors, LLC
212-915-2578



Source: Soleno Therapeutics